Headlines > All Ingredients News
Adjuvant debuts in new hep B vaccine
09-Feb-2005 - The European approval of a new high-potency vaccine for hepatitis B virus (HBV) marks the debut on the marketplace of a new adjuvant ingredient that can significantly improve the effectiveness of immunisations, reports Phil Taylor.
Alkermes to file first 'homegrown' product
08-Feb-2005 - US drug delivery company Alkermes has entered a new stage in its development as it gears up to file for marketing approval of its own product, rather than applying its technologies to drugs sold by customers.
India begins its first human AIDS trial
08-Feb-2005 - India begins its first ever human clinical trial of an investigational vaccine candidate designed to treat HIV/AIDS, which now has a worldwide infection rate of 14,000 every day.
Substance protects resilient Staph bacteria
08-Feb-2005 - Researchers have identified a promising new drug target in their fight against resilient Staphylococcus bacteria that can be transmitted to patients in hospitals via contaminated medical implants.
EC takes aim at another chemicals cartel
07-Feb-2005 - The European Commission has charged 18 chemical firms with conspiring to fix prices of hydrogen peroxide and derivatives sodium perborate and sodium percarbonate.
Fertin and Perrigo take on US nicotine gum players
07-Feb-2005 - US drugmaker Perrigo has started selling a new nicotine gum to help smokers quit the habit in the US, challenging the dominance there of Pfizer and GlaxoSmithKline's Nicorette product.
Richter Gedeon has mixed fortunes in 2004
07-Feb-2005 - Hungary's Richter Gedeon reported rises in both overall sales and profits in 2004, although its active pharmaceutical ingredient (API) business remained under pressure in the US.
Excipient industry calls for Euro master file system
04-Feb-2005 - The pharmaceutical excipients industry urgently needs a system of European master files, already used by the active pharmaceutical ingredient sector (API), to stimulate innovation in the sector and bring Europe's regulatory stance in line with the US. Phil Taylor reports.
Hana initiates trials of PT-523 for lung cancer
04-Feb-2005 - Hana Biosciences announced today the clinical trial initiation of PT-523 to evaluate this compound as a single agent in relapsed non-small cell lung cancer (NSCLC). Lung cancer continues to carry the poorest prognosis of cancer, with a five-year survival rate of just 10 -15 per cent.
Protein modification technology patented by Bolder
04-Feb-2005 - US firm Bolder BioTechnology has been awarded a patent for a new technology that allows therapeutic proteins to be modified chemically to improve its activity in the body.
Next-gen renin inhibitor results encouraging
04-Feb-2005 - Speedel Experimenta has announced the completion of its human micro-dosing studies into renin inhibitors that are set to provide an effective means of treating hypertension and for protecting end organs such as the heart and kidneys.
BASF backs novel encapsulation technology
04-Feb-2005 - Chemicals giant BASF has invested €2 million in a small German encapsulation business that claims to have developed a novel process that allows for efficient ingredient delivery.
GPC Biotech starts trials of cancer antibody
03-Feb-2005 - GPC Biotech announced the initiation of a Phase I trial with its anticancer monoclonal antibody, 1D09C3, which has already proved effective in the treatment of lymphoid tumours including non-Hodgkin's lymphoma.
Excipient industry's future under debate
02-Feb-2005 - The pharmaceutical industry is under pressure from downwards price pressure, a lack of innovation, and the escalating costs of new product development, and this is having a knock-on effect for excipients suppliers. Phil Taylor reports.
PEG makes tablets out of injectables
01-Feb-2005 - NOBEX has been granted two new US patents on its polyethylene glycol (PEG)-based technologies to improve the delivery of drugs that currently need to be injected.
Lanxess debuts on Frankfurt exchange
31-Jan-2005 - Lanxess, the chemicals and polymers spin-out of Germany's Bayer, made its debut on the Frankfurt stock exchange this morning.
Acatris launches directly compressible SoyLife
31-Jan-2005 - Health ingredients firm Acatris has developed a directly compressible version of its SoyLife brand soy isoflavone ingredient, designed to remove some of the hurdles for companies looking to offer isoflavone capsules or tablets.
Neuro3d initiates depression trials with ND7001
28-Jan-2005 - A new type of antidepressant drug with a novel mechanism of action, which acts on a new target, has entered Phase I clinical trials. The drug could represent a new generation of psycho-active compounds that are devoid of the problems seen with existing treatments.
Neich acquires Orbus Medical Tech
27-Jan-2005 - Neich Medical has acquired Orbus Medical Technologies in which Orbus is leading Neich's research and development efforts for drug eluting stents and other advanced technologies.
Bayer plans inhaled Cipro for cystic fibrosis
27-Jan-2005 - Bayer is to collaborate with Nektar on the development of an inhaled formulation of Cipro (ciprofloxacin) for treating the common genetic disorder cystic fibrosis.
Lonza still under pressure in 2004
27-Jan-2005 - Swiss chemicals and contract manufacturing concern Lonza reported a decline in sales but net profit up by more than half in 2004, although earnings came in at the low end of analysts' forecasts.
DNT, Dow & Starpharma in 3-way dendrimer deal
27-Jan-2005 - A unique three-way-deal between Dendritic Nanotechnologies (DNT), The Dow Chemical Company and Starpharma Holdings, will provide DNT and Starpharma with access to dendrimers and nanotechnology for drug delivery.
Dow spins out dendrimer portfolio to nanotech firm
26-Jan-2005 - Dow Chemical has signed over its entire portfolio of intellectual property and technology in the area of dendrimers - branched polymers with applications in targetted drug delivery - to US firm Dendritic NanoTechnologies and Starpharma of Australia.
New active agents against leishmaniasis
26-Jan-2005 - Scientists have targeted the alkaloids of the quinolines chemical family, which have proved effective against visceral leishmaniasis treating this severe form of the disease with its antiparasitic properties.
Nanotech could be answer to gene therapy delivery
25-Jan-2005 - Researchers in the US have shown that nanoparticles can be used to deliver genetic material into cells safely and effectively, potentially overcoming the primary obstacle to the development of gene therapy.
Ingredients: Most Popular News
Spotlight
  ICH sends Q11 guidelines to EU, US & Japanese regulatorsThe ICH has sent its Q11 guidelines on APIs to regulatory bodies in the US, European Union... |
  in-Pharmatechnologist.com's review of Interphex 2012in-Pharmatechnologist.com was at Interphex 2012 in New York, US to launch the revamped version of our website and speak... |
 Effective controls still lacking for continuous processing says Interphex panelContinuous processing is still hamstrung by a lack of control systems and is not ready for specific... |
 BASF buys omega-3 maker Equateq citing pharma potentialBASF has bought omega-3 fatty acid maker Equateq, citing its pharmaceutical and dietary supplements businesses as key... |
 EMA outlines manufacturing quality docs for biologics trialsThe EMA has published final guidelines on manufacturing quality documents needed for biologics entering clinical trials. |